

Pemetrexed in Third and Fourth Line Chemotherapy for Non Squamous Non Small-Cell Lung Cancer

Alexandru Calin Grigorescu*

Department of Medical Oncology, Institute of Oncology Prof. Dr. Alexandru Trestioreanu, Bucharest, Romania

*Corresponding author: Alexandru Calin Grigorescu, Department of Medical Oncology, Institute of Oncology Prof. Dr. Alexandru Trestioreanu, Bucharest, Romania, Tel: +40212271070; E-mail: alexgrigorescu2004@yahoo.com

Received date: February 15, 2017; Accepted date: February 27, 2017; Published date: March 06, 2017

Copyright: © 2017, Grigorescu AC. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract

Introduction: Lung cancer is responsible for the highest mortality caused by malignant solid tumors. Chemotherapy remains one of the most important modality of treatment.

Methods: This retrospective study analyzed the records of 42 patients' treatment with pemetrexed, used in second, third and fourth line chemotherapy for advanced non-squamous non-small cell cancer (NSCLC). Kaplan Meier curve was used for calculation of overall survival.

Results: The median overall survival in the second-line was 10 months and in third- and fourth-line was 6.5 months.

Discussion: We discuss the similar study with pemetrexed in mono-chemotherapy or combination, study with similar results. Also we make a reference to the new therapy with best results but with much higher cost and effective only for a part of patients.

Conclusions: This result and other results presented in similar studies encourage us to recommend pemetrexed in the third and fourth line chemotherapy for well-selected patients.

Keywords Lung cancer; Chemotherapy; NSCLC; Treatment

Background

Lung cancer determines the highest mortality by cancer in Europe, accounting for approximately 20% of all cancer deaths 1.38 million deaths in 2008 in the world and 376 000 only in Europe. The majority of cases occur after 60 years old (29% 60–69 years of age and 44% were over 70 years of age). At this time the overall 5-year survival in lung cancer is only 11.2% for men and 13.9% for women. However, recent discoveries in the biology of lung cancer promise new more efficient therapies [1]. The situation is similar in Unites States, where lung cancer is also the leading cause of cancer-related mortality [2].

Platinum-based chemotherapy remains the standard first-line treatment for a NSCLC. Somehow a standard for second-line chemotherapy for a NSCLC is represented by docetaxel or pemetrexed. The third-line and fourth-line of chemotherapy are poorly defined.

In 2009, the only proven third-line agent was Erlotinib, based on the same trial that led to the drug's approval in second-line therapy, and there are no drugs that have a proven benefit either for survival or for improved QOL after that. At the present time, immunotherapy with check inhibitors demonstrated an improvement in survival when they were used in second line therapy, but the trend is to move this therapy in the first line [3,4].

We were encouraged in our approach to this study by the American Society of Clinical Oncology (ASCO) Cancer Research Committee considers that a relative improvement in median OS of at least 20%

(3-4 months) is regarded to define a clinically meaningful improvement in the outcome of NSCLC patients [5]. We suppose that pemetrexed in third line could reach this goal.

The existing possibilities for chemotherapy in second-line for advanced NSCLC in 2009 were represented by three agents: docetaxel, erlotinib and pemetrexed. These three drugs show that they can modestly prolong survival when the disease progressed after the first-line chemotherapy. At that time, there was only one proven third-line agent (Tarceva-Erlotinib), based on the same trial that led to the drug's approval in second-line therapy (BR21) [6,7].

Aims

This study tries to demonstrate that in particular cases pemetrexed could be a treatment option for advanced non-small cell lung cancer (NSCLC) with non-squamous histology in second-line, third-line and fourth-line chemotherapy, taking in consideration that the new drugs are very expensive and we didn't explore sufficiently chemotherapy with actual best supportive care.

Methods

Twenty-six patients were evaluated retrospectively after the second-line treatment with pemetrexed (P), and 16 patients were evaluated after third and fourth line. The evaluation was performed by using the written data from the medical records of the Institute of Oncology from Bucharest. The enrollment was done successively using the first data of presentation of the patients in institute for the treatment in the

first line. We have studied the population of patients treated with pemetrexed in second line in the same period of time with patients treated in third and fourth line in order to demonstrate that it is a homogenous population and the value of overall survival in second line is registered in the values cited in literature. We do not mean to compare the two groups of patients. The criteria of selections were:

- Age between 18 to 80 years old,
- The administration of second line, third line or fourth line of chemotherapy,
- Existing imaging data evaluation of response after two or three cycles of chemotherapy,
- Existing data about the main toxicity,
- Use of erlotinib in the first or second line was permitted,
- Palliative radiotherapy for mediastinal compression, bone pain, hemoptysis was also permitted.

Overall survival was calculated for patients included in each line of therapy using the Kaplan Meier curve. The toxicity was appreciated using the WHO criteria.

Results

In the second-line, third-line and fourth-line chemotherapy groups, the characteristic of patients were similar (age, stage of disease, histology). The median age for patients treated in second line with pemetrexed was 57-years-old and 62 years-old for those treated in third and fourth line. The difference was in the number of men and women in the two lots. In the lot treated in second-line, this number was equal, but in the group treated in third- and fourth-line chemotherapy, there were 3 times more men than women.

Other characteristics of patients and the main results in survival for the two groups can be observed in Tables 1-4 and in Figures 1 and 2.

Sex	
Male	13 (50%)
Femele	13 (50%)
Age (median years)	57 (37-80)
Stage	
IIIB	3 (11.5%)
IV	23 (88.5%)

Table 1: Baseline characteristics of 26 patients treated with pemetrexed in second line chemotherapy

Discussions

We will discuss predominantly the study which tested pemetrexed in third line, especially the retrospective study. Also, we will discuss about the association of pemetrexed with other drugs in third line and the new trend.

In 2006, Kumar et al. recognized the possibility of third-line chemotherapy and beyond for responders to the first-line chemotherapy and good performance status patients. The authors quated like candidates for third-line chemotherapy: single-agent gemcitabine, irinotecan, and oral topotecan [8].

First line chemotherapy
Paclitaxel+Carboplatin
Paclitaxel+Carboplatin+Bevacizumab (small number of patients because patients must wait for approval from the Nnational Ensurance Commission)
Docetaxel+Carboplatin
Carboplatin+Vinorelbine
Alimta+Cisplatin or Carboplatine (small number of patients because patients must wait for approval (small number of patients because patients must wait for approval from the Nnational Ensurance Commission)
Gemcitabine+Cisplatine or carboplatine
Erlotinib
Other
Average number of cycles: 4 (2–8)

Table 2: First line chemotherapy for NSCLC used in Institute of Oncology, Bucharest, for this lot of patients.

Sex	
Male	12 (75%)
Female	4 (25%)
Age (median years)	62 (31–80)
Stage	
IIIB	4
IV	12

Table3: Baseline characteristic of patients treated with Pemetrexed in third and fourth line chemotherapy (16 patients: 12 in third line, 4 in forth line).

Hematologic side effects
Mild anemia in 3 case
Leucopenia 2 cases
Nonhematologic side effects
GPT elevation 2 cases
Creatinin elevation 1 case
LDH elevation 1 case
Others
dizziness (1), fatigue (1), lack of appetite (2)

Table 4: Side effects.

The study published by Song et al. was a retrospective study which confirmed the small but proved benefit of third-line chemotherapy. The authors found the progression-free survival after third-line therapy to be 2.37 months for all patients and 2.30 months for patients

treated with doublet of cytostatics, 2.80 months for single-agent and 2.97 months for EGFR-TKIs arms ($P=0.033$) [9].




Figure 1: Median overall survival of patients treated with pemetrexed in second line.




Figure 2: Median overall survival of patients treated with pemetrexed in third and fourth line.

One of the first studies which tested the use of pemetrexed in third-line chemotherapy for advanced NSCLC was a retrospective study of Jong-Mu et al. In this study, the medical records of NSCLC patients who received pemetrexed therapy that progressed after systemic therapy were reviewed retrospectively. The authors stratified patients according to clinic-pathologic characteristics to find predictive factors for pemetrexed therapy. The conclusion was that pemetrexed is a suitable third-line treatment option with a good toxicity profile [10].

Adolfo G. Favaretto described in a review published in 2009, in which was stipulated that because pemetrexed had a good toxicity profile, elderly and patients with performance status 3, for which the ASCO guidelines contraindicate any chemotherapy, could benefit from pemetrexed (Weiss et al., Zinner et al.) [11]. Taking into consideration this aspect, we presumed that pemetrexed can be used in the third line therapy, where patients often have a bad performance status.

Another observational study that refers to pemetrexed in third-line therapy was published in 2014. This study compared pemetrexed alone in third line with pemetrexed plus bevacizumab in third-line chemotherapy for patients with positive EGFR mutation. The conclusion of this study was that "regardless of the order of the first- and second-line chemotherapy and TKI therapy, the pemetrexed plus

bevacizumab regimen was superior to the pemetrexed monotherapy as the third-line therapy in patients with advanced EGFR-positive lung adenocarcinoma". However, the authors recommend further investigation in prospective studies [12].

Another study similar with ours evaluated the clinical outcome of third and fourth-line chemotherapy for the treatment of advanced NSCLC in consecutive patients who received first-line chemotherapy in the same institution. A global result was that the median survival periods (95% confidence interval [CI]) from the start of first-, second-, third-, and fourth-line chemotherapy until death were 15.3 months. The authors concluded that in their study more than 38% of patients with advanced NSCLC could receive third-line chemotherapy, and it is a need for randomized controlled trials of third-line chemotherapy in patients with advanced NSCLC [13]. The possible option for third line chemotherapy has been also highlighted in other studies [14,15].

Other therapeutic approaches in second-line and third-line therapy

Overall survival was significantly longer with nivolumab than with docetaxel at the time of the interim analysis (minimum follow-up for overall survival: 13.2 months), the median overall survival was 12.2 months (95% confidence interval [CI], 9.7 to 15.0) with nivolumab and 9.4 months (95% CI, 8.1 to 10.7) with docetaxel, representing a 27% lower risk of death with nivolumab (hazard ratio: 0.73; 96% CI, 0.59 to 0.89; $P=0.002$). The overall survival rate at 1 year was 51% (95% CI, 45 to 56) with nivolumab and 39% (95% CI, 33 to 45) with docetaxel. These results reveal the fact that the overall survival for some patients could be prolonged with approximately 3 months. We must also take in consideration the toxicity of docetaxel—if it could be reduced, maybe we had other results with docetaxel. But, obviously, is a step forward in NSCLC therapy [16].

The researchers consider that a new step in the optimization of the treatment of advanced NSCLC is the association between immunotherapy agents (especially inhibitors of PD-1/PD-L1 and TKI). For the moment, the correlation between PD-1/PD-L1 expression and EGFR expression was not elucidated, and needs more evidence to support this combination [17].

Zhen Ying Geng and collab compared 4 groups of patients: the EGFR-TKIs group, the single-agent chemotherapy group, the combination chemotherapy group and the chemo-targeted group. The main parameters compared in this study, partial response, progression-free survival and overall survival showed no statistically significant difference [18]. These results show that chemotherapy remains an important option for selected patients in second-line and third-line therapy.

In the 1st ESMO Consensus Conference in Lung Cancer (Lugano, 2010), the three analyzed options for second-line and third-line chemotherapy showed that more evidence seems to be in third-line therapy for epidermal growth factor receptor inhibitors [19].

In a study of researchers from Sevilla (Spain), it was concluded that: "erlotinib/gefitinib and crizotinib, which target EGFR and ALK, are the only recommended agents for third-line therapy in patients with advanced/metastatic NSCLC". But the authors revealed the fact that in real world, in clinical practice, a variety of chemotherapeutic agents was used in this setting was emphasized the need for new agents and complementary biomarker analysis to predict the response to these

agents and to identify those patients most likely to benefit from them [20].

In a study published in 2010, it is mentioned that third-line chemotherapy for advanced non-small cell lung cancer (NSCLC) was accepted as a reasonable therapeutic option in patients with a favorable performance status. So author studied a total of 82 records of patients with NSCLC treated by platinum based chemotherapy in first line; 33 of these patients were candidates in third-line chemotherapy or more. The median survival was 23 months for patients treated with more than third-line chemotherapy, compared to 7 months for patients treated with less than second-line chemotherapy. The authors concluded that long-standing chemotherapy is not beneficial to all NSCLC patients. However, patients with a favorable response to first-line chemotherapy tend to receive a higher number and more cycles of chemotherapy than the non-response group. Another conclusion was that multi-line chemotherapy appears to increase survival in the response group. Further studies are needed to confirm these results [21].

Conclusion

We analyzed patients treated in third-line and fourth-line chemotherapy for NSCLC. We could use this chemotherapy because the third-line and fourth-line treatment in advanced NSCLC is not well defined and for some countries the immunotherapy and other modern therapies are not available. Taking into consideration the ASCO recommendation – “relative improvement in median OS of at least 20% (3-4 months) is regarded to define a clinically meaningful improvement in outcome of NSCLC patients” – we can conclude that pemetrexed reaches this goal. It was proved that patients who had a good response to first-line and second-line chemotherapy have a chance to also respond to the third-line and fourth-line chemotherapy.

Finally, we concluded that for selected patients with advanced non-squamous NSCLC, namely those who responded to first-line and second-line chemotherapy or to erlotinib, pemetrexed can be administered in third-line and fourth-line, with survival benefits and acceptable toxicity. A large study is necessary to confirm the data obtained in this study.

References

1. European Respiratory Society (2013) Lung Cancer. European Lung white book.
2. (2015) Non-Small Cell Lung Cancer Treatment (PDQ). Siteman Cancer Center.
3. Gregory A, Shah D (2016) Immunotherapy in Lung Cancer Treatment: Current Status and Future Directions. ASCO Annual meetings, Chicago.
4. Nelson R (2015) DA Approves Pembrolizumab for Lung Cancer. Medscape.
5. Fenchel K, Sellmann L, Dempke WC (2016) Overall survival in non-small cell lung cancer—what is clinically meaningful? *Transl Lung Cancer Res* 5: 115-119.
6. Gadgeel S (2009) Who Benefits from Third-line Treatment for Advanced NSCLC? Global resource for advancing cancer education.
7. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, et al. (2005) Erlotinib in previously treated non-small-cell lung cancer. *N Engl J Med* 53: 123-132.
8. Kumar A, Wakelee H (2006) Second- and third-line treatments in non-small cell lung cancer. *Curr Treat Options Oncol* 7: 37-49.
9. Song Z, Yu Y, Chen Z, Lu S (2011) Third-line therapy for advanced non-small-cell lung cancer patients: feasible drugs for feasible patients. *Med Oncol* 28 Suppl 1: S605-S612.
10. Sun JM, Lee KW, Kim JH, Kim YJ, Yoon HI, et al. (2009) Efficacy and toxicity of pemetrexed as a third-line treatment for non-small cell lung cancer. *Jpn J Clin Oncol* 39: 27-32.
11. Favaretto AG, Pasello G, Magro C (2009) Second and third line treatment in advanced non-small cell lung cancer. *Discov Med* 8: 204-209.
12. Zhou CZ, Qin YY, Xie ZH, Zhang JX, Ou-Yang M, et al. (2014) Efficacy of third-line pemetrexed monotherapy versus pemetrexed combination with bevacizumab in patients with advanced EGFR mutation-positive lung adenocarcinoma. *Chin J Cancer Res* 26: 705-710.
13. Asahina H, Sekine I, Horinouchi H, Nokihara H, Yamamoto N, et al. (2012) Retrospective analysis of third-line and fourth-line chemotherapy for advanced non-small-cell lung cancer. *Clin Lung Cancer* 13: 39-43.
14. Özdogan M, Samur M, Bozcuk H, Coban E, Artaç M, et al. (2004) Is the third-line chemotherapy feasible for non-small cell lung cancer? A retrospective study. *Turkish J Cancer* 34: 1.
15. Kanat O, Ölmez F, Kurt E, Yıldız A, Evrensel T, et al. (2006) Single-agent vinorelbine as third-line chemotherapy for refractory non-small cell lung cancer. *Turkish J Cancer* 36: 3.
16. Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, et al. (2015) Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. *N Engl J Med* 373: 1627-1639.
17. Ji M, Liu Y, Li Q, Li X, Ning Z, et al. (2015) PD-1/PD-L1 expression in non-small-cell lung cancer and its correlation with EGFR/KRAS mutations. *Cancer Biol Ther* 17: 407-413.
18. Ying Geng Z, Chang Jiao S, Cui Liu S, Li Y, Feng Liu Z, et al. (2013) Third-line therapy in advanced non-small cell lung cancer. *J BUON* 18: 899-907.
19. Felip E, Gridelli C, Baas P, Rosell R, Stahel R (2011) Panel Members, Metastatic non-small-cell lung cancer: Consensus on Pathology and Molecular Tests, First-Line, Second-Line, and Third-Line Therapy: 1st ESMO Consensus Conference in Lung Cancer; Lugano 2010. *Ann Oncol* 22: 1507-1519.
20. Jaime JC, de la Peña MG, Alonso M, Gastaldo AS, Mediano MD, et al. (2013) Hospital Universitario Virgen del Rocío, Sevilla, Third-line therapy and beyond for patients with advanced/metastatic non-small cell lung cancer (NSCLC). *J Clin Oncol* 31: e19160.
21. Park SJ, Choi IK, Seo HY, Sung HJ, Park KH, et al. (2010) Treatment results including more than third-line chemotherapy for patients with advanced non-small cell lung cancer. *Oncol Lett* 1: 51-55.